Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
3.
Neurogastroenterol Motil ; 28(7): 994-1000, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-26914655

RESUMO

BACKGROUND: The cost-effectiveness for screening for celiac disease (CD) in patients with irritable bowel syndrome (IBS), specifically in the diarrhea (IBS-D) subtype, is beneficial if the prevalence is >1%. However, recent studies have shown controversial results. In this large case-control study, our aim was to determine the prevalence of CD and a panel of related antibodies in patients diagnosed with IBS. MATERIALS AND METHODS: Four hundred IBS patients (Rome III) and 400 asymptomatic healthy controls were prospectively evaluated using antihuman tissue transglutaminase (h-tTG IgA) and deamidated gliadin peptide antibodies (DGP II IgA and DGP II IgG). Duodenal biopsy was performed on the patients that were positive for the h-tTG IgA and/or DGP II IgG antibodies. RESULTS: The mean age of the population was 44.47 ± 18.01 years and 335 (82%) of the subjects were women. Twenty-one patients and six controls had at least one positive test for CD (5.25% VS 1.5%, p = 0.003, OR 3.63 [95% CI 1.4-9.11]). Eighteen patients were positive for h-tTG and/or DGP-II IgG. Histologic confirmation of CD was 2.5% in the IBS patients vs 0.5% in the controls (p = 0.04, OR 5.21). The IBS-D subtype had the highest prevalence for serological positivity (12.7%). CONCLUSIONS: Up to 5.2% of the patients with IBS according to the Rome III criteria were positive for at least one of the CD-related antibodies and 2.5% had biopsy-confirmed CD. Therefore, in our population, screening for CD in subjects with IBS appears to be a reasonable strategy, especially in the IBS-D subgroup.


Assuntos
Autoanticorpos/sangue , Doença Celíaca/sangue , Doença Celíaca/epidemiologia , Síndrome do Intestino Irritável/sangue , Síndrome do Intestino Irritável/epidemiologia , Adulto , Estudos de Casos e Controles , Doença Celíaca/classificação , Feminino , Humanos , Imunoglobulina A/sangue , Síndrome do Intestino Irritável/classificação , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Prospectivos
4.
Rev Gastroenterol Mex ; 75(1): 36-41, 2010.
Artigo em Espanhol | MEDLINE | ID: mdl-20423781

RESUMO

BACKGROUND: Irritable bowel syndrome (IBS) is recognized as the most frequent functional digestive disorder around the world. In Latin America and Mexico there are few studies in order to demonstrate its real prevalence in general population. AIMS: To determine the prevalence of IBS in general population from Veracruz City Mexico, using the Rome II criteria. MATERIAL AND METHODS: Using basic information given by bureau for planning urban services from Veracruz country, a 10% random population sample was obtained. Subjects between 16-80 years old were interviewed using a questionnaire based on Rome II criteria and a visual analogous scale in order to estimate the negative effect of IBS symptoms on daily activities. RESULTS: We interviewed 459 subjects with a median age of 31.2 +/- 13.6 years old detecting 78 subjects (16.9%) with IBS symptoms: 25 males and 53 females (gender prevalence of 11.3% and 22.1%, respectively). 28.2% of them had IBS with diarrhea, 50% had IBS with constipation and 21.8% alternating bowel movements, diarrhea and constipation. Negative effect of IBS symptoms on daily activities was significant. CONCLUSIONS: The prevalence of IBS in open population was 16.9% according to Rome II criteria, being higher in those older than 35 years old. Constipation was the predominant pattern. Further studies should evaluate associated factors of these findings.


Assuntos
Síndrome do Intestino Irritável/epidemiologia , Adulto , Feminino , Inquéritos Epidemiológicos , Humanos , Masculino , México/epidemiologia , Prevalência , Estudos Retrospectivos , Saúde da População Urbana
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...